Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 8 art units • 15 examiners • 0 of 18 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Merus N V has 17 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 14 examiners and 8 art units, showing substantial examiner diversity alongside repeated art-unit activity. The art-unit concentration provides an opportunity to track recurring technical treatment, but the examiner distribution requires individualized prosecution management.
WEHBE, ANNE MARIE SABRINA is the busiest examiner, handling 2 pending matters. The leading examiner assignment is limited relative to the full portfolio, so it should inform coordination without becoming the sole basis for prosecution planning.
A centralized review of claim language, technical disclosures, and prior-art positions can support consistency across related matters. Responses should still be tailored to the particular examiner and art unit, especially where biotechnology claims raise distinct issues across the examination tracks.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (11%) |
| §102 only | 1 (6%) |
| §112 only | 4 (22%) |
| Double-patenting + other | 3 (17%) |
| Multi-statute (no §101) | 7 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 2 | 57.3% | +43.3% |
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 57.4% | +30.7% |
| CHASE, CAROL ANN | 1 | 41.9% | +84.9% |
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18084797 | BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1 | XIAO, YAN | 69d |
| 18398935 | PROMISCUOUS CD3 BINDING MOLECULES | CHASE, CAROL ANN | — |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | HOPPE, EMMA RUTH | — |
| 18460482 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | — |
| 18449460 | ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | LI, RUIXIANG | — |
| 18190607 | METHOD FOR DETECTING EXPRESSION OR CLUSTERING OF CELL SURFACE MOIETIES | DUNN, MCKENZIE A | — |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 6d |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 27d |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | BRISTOL, LYNN ANNE | 70d |
| 18398935 | PROMISCUOUS CD3 BINDING MOLECULES | CHASE, CAROL ANN | — |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | HOPPE, EMMA RUTH | — |
| 18553114 | NOVEL MULTISPECIFIC ANTIBODIES | DONOGHUE, BRITTNEY ERIN | — |
| 18464173 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 5 |
| 1646 | 3 |
| 1642 | 3 |
| 1634 | 2 |
| 1674 | 2 |
| 1683 | 1 |
| 1675 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18398935 | PROMISCUOUS CD3 BINDING MOLECULES | CHASE, CAROL ANN | 1646 | §102§112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18566982 | NEW NRG1 FUSIONS, FUSION JUNCTIONS AND METHODS FOR DETECTING THEM | HOPPE, EMMA RUTH | 1683 | §101§102§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18553114 | NOVEL MULTISPECIFIC ANTIBODIES | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18464173 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | 1634 | §102 | Final Rejection | — | Pending | Sep 08, 2023 |
| 18460482 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | 1634 | §102§103§112Other | Final Rejection | — | Pending | Sep 01, 2023 |
| 18449460 | ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | LI, RUIXIANG | 1674 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18257804 | MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | NICKOL, GARY B | 1643 | §103 | Final Rejection | — | Pending | Jun 15, 2023 |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 1642 | §102§103§112DP | Final Rejection | 6d | Pending | May 04, 2023 |
| 18190607 | METHOD FOR DETECTING EXPRESSION OR CLUSTERING OF CELL SURFACE MOIETIES | DUNN, MCKENZIE A | 1678 | §102§103§112 | Final Rejection | — | Pending | Mar 27, 2023 |
| 18084797 | BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1 | XIAO, YAN | 1642 | §102§112Other | Final Rejection | 69d | Pending | Dec 20, 2022 |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | MOSELEY II, NELSON B | 1642 | §112 | Final Rejection | 22d | Pending | Dec 07, 2022 |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 27d | Pending | Nov 18, 2022 |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | SHUPE, ELIZABETH A | 1643 | §103DP | Non-Final OA | 29d | Pending | Oct 24, 2022 |
| 17759728 | MEANS AND METHOD FOR MODULATING IMMUNE CELL ENGAGING EFFECTS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | — | Pending | Jul 29, 2022 |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 70d | Pending | Apr 22, 2022 |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | MIDDLETON, DANAYA L | 1674 | §103§112DP | Non-Final OA | 28d | Pending | Feb 01, 2022 |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112 | Final Rejection | 30d overdue | Pending | Aug 13, 2021 |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Aug 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMerus N V has 18 pending office actions as of October 2026, spread across 8 art units and 15 examiners.
Anne Marie Sabrina Wehbe has the most, with 2 of Merus N V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
